10-Q: SCYNEXIS Q2 Net Loss Halves Amid GSK Dispute, Nasdaq Warning

SCYNEXIS reported a significant reduction in net loss for Q2 2025, driven by a warrant liability fair value adjustment, while navigating a dispute with GSK over the MARIO study and a Nasdaq minimum bid price deficiency.

Summary

• Net loss for the three months ended June 30, 2025, significantly decreased to $6.9 million from $14.5 million in the prior year, primarily due to a favorable warrant liability fair value adjustment.
• Net loss for the six months ended June 30, 2025, decreased to $12.3 million from $14.0 million in the prior year.
• License agreement revenue increased by 85.3% to $1.4 million for the three months ended June 30, 2025, but decreased by 23.2% to $1.6 million for the six months ended June 30, 2025.
• The FDA lifted the clinical hold on the Phase 3 MARIO study for ibrexafungerp on April 24, 2025, and patient dosing resumed in May 2025.
• GSK notified of its intention to terminate the MARIO study on April 28, 2025, disputing $30.0 million in development milestones, a claim SCYNEXIS contests.
• SCYNEXIS billed GSK a $10.0 million development milestone in Q2 2025 following the resumption of patient dosing in the MARIO study.
• The company completed the single and multiple ascending dose portions of its Phase 1 study for oral SCY-247 and expects to release data in Q3 2025.
• Received a Nasdaq notification on June 20, 2025, regarding non-compliance with the $1.00 minimum bid price rule, with a compliance deadline of December 17, 2025.
• Cash and cash equivalents and investments totaled $46.5 million as of June 30, 2025, down from $75.1 million at December 31, 2024.
• The $14.0 million March 2019 convertible notes were fully repaid in March 2025.
• Accumulated deficit increased to $388.8 million as of June 30, 2025.

Sentiment

Score: 4

Explanation: While the net loss decreased, this was largely due to a non-cash warrant adjustment. The core operational challenges, particularly the significant dispute with GSK over the MARIO study and associated milestones, coupled with the Nasdaq delisting warning and declining cash reserves, present substantial headwinds and uncertainty. The progress on SCY-247 is a positive, but overshadowed by these larger issues.

Positives

• Net loss significantly reduced by 52.4% to $6.9 million for the three months ended June 30, 2025, compared to $14.5 million in the prior year.
• FDA lifted the clinical hold on the Phase 3 MARIO study for ibrexafungerp on April 24, 2025.
• Patient dosing in the Phase 3 MARIO study resumed in May 2025, triggering a $10.0 million development milestone billed to GSK.
• Completed Phase 1 study portions for SCY-247, with data expected in Q3 2025.
• Fully repaid $14.0 million in convertible debt in March 2025, reducing liabilities.
• GSK reiterated commitment to continued collaboration on BREXAFEMME commercialization for VVC and RVVC indications.

Negatives

• GSK notified intent to unilaterally terminate the MARIO study and disputes $30.0 million in development milestones, creating significant uncertainty.
• Received a Nasdaq notification on June 20, 2025, for failing to meet the $1.00 minimum bid price requirement, risking delisting.
• Cash and cash equivalents and investments decreased to $46.5 million as of June 30, 2025, from $75.1 million at December 31, 2024.
• Accumulated deficit increased to $388.8 million as of June 30, 2025.
• License agreement revenue for the six months ended June 30, 2025, decreased by 23.2% to $1.6 million.
• Ongoing securities class action and shareholder derivative complaints related to alleged misstatements and cross-contamination risks.

Risks

• Failure to resolve the disagreement with GSK regarding the MARIO study and associated development milestones could materially impact financial statements and future commercialization of ibrexafungerp for invasive candidiasis.
• Inability to regain compliance with Nasdaq's $1.00 minimum bid price rule by December 17, 2025, could lead to delisting, negatively impacting stock price and access to capital markets.
• Liquidity could be materially affected by the ability to raise additional capital, costs of strategic alliances, negative regulatory events, unanticipated costs for SCY-247 and ibrexafungerp development, and ability to achieve GSK License Agreement milestones.
• The company may need to delay expenditures, reduce research and development program scope, or make significant changes to its operating plan if unable to meet obligations.
• The successful development of product candidates is highly uncertain, and the nature, timing, or costs to complete remaining development cannot be reasonably estimated.
• Ongoing legal proceedings (securities class action and shareholder derivative complaints) could result in unspecified damages, disgorgement, and other costs.

Future Outlook

The company expects to continue incurring significant research and development and selling, general and administrative expenses. It anticipates needing substantial additional funding to support ongoing operations and future development activities, which may be sourced through equity offerings, debt financings, third-party funding, or strategic alliances. The successful development of product candidates remains highly uncertain, and the timing and costs to complete development cannot be reasonably estimated.

Management Comments

• "We do not believe that GSK currently has the right to unilaterally terminate the MARIO study under the GSK License Agreement."
• "We are seeking to resolve this disagreement with GSK."
• "We reinitiated the MARIO study and patient dosing resumed in the Phase 3 MARIO study in May 2025, triggering us to bill a $10.0 million development milestone to GSK."
• "We are seeking to collect our development milestones from GSK and ultimately complete the study."
• "While at this time it is too early to say how this disagreement may be resolved, GSK has reiterated its commitment to continued collaboration regarding other aspects of the GSK License Agreement including with respect to the commercialization of BREXAFEMME for the VVC and RVVC indications."
• "We remain committed to developing novel antifungal solutions to the rising threat of deadly fungal infections including invasive candidiasis for which there are limited treatment options and significant concerns for emergence of resistances, as highlighted by the WHO in their call to industry and other parties for research, development and public health action in this area of unmet need."
• "We expect to release the single ascending and multiple ascending dose data [for SCY-247] in the third quarter of 2025."
• "We believe our capital resources are sufficient to fund our on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements."

Industry Context

SCYNEXIS operates in the biotechnology sector, specifically focusing on antifungal medicines for difficult-to-treat and drug-resistant infections, an area highlighted by the WHO as having significant unmet needs. The development of novel fungerps like ibrexafungerp and SCY-247 positions the company in a niche market addressing critical public health challenges. The dispute with GSK, a major pharmaceutical company, underscores the complexities and risks inherent in large-scale licensing and development partnerships within the industry, particularly concerning milestone payments and study continuation. The recall of BREXAFEMME due to manufacturing issues also reflects the stringent regulatory and quality control demands in pharmaceutical production.

Legal Proceedings

• Securities class action filed November 7, 2023, alleging materially false/misleading statements and failure to disclose cross-contamination risk for ibrexafungerp between March 31, 2023, and September 22, 2023. The court granted a motion to dismiss with leave to amend on July 30, 2025.
• Shareholder derivative complaints filed May 1, 2024, and June 4, 2024, naming directors and officers, asserting state and federal claims based on the same alleged misstatements as the class action. These cases are consolidated and stayed.
• The company disagrees with the allegations and intends to vigorously defend these litigations.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, risk of delisting from Nasdaq, uncertainty regarding the GSK dispute impacting future revenue and stock value, and ongoing legal proceedings.
• Employees: Continued focus on research and development for SCY-247 and ibrexafungerp, but potential for operational changes if funding is constrained.
• Customers (patients/healthcare providers): Continued development of novel antifungal solutions, but potential delays or uncertainties in product availability (e.g., BREXAFEMME reintroduction, MARIO study outcome).
• GSK: Ongoing dispute over MARIO study and milestone payments, but reiterated commitment to VVC/RVVC commercialization.
• Creditors: Convertible debt fully repaid, reducing immediate debt obligations.

Next Steps

• Resolve the disagreement with GSK regarding the MARIO study and collection of development milestones.
• Complete the Phase 3 MARIO study for ibrexafungerp.
• Release single and multiple ascending dose data for the Phase 1 study of oral SCY-247 in Q3 2025.
• Regain compliance with Nasdaq's $1.00 minimum bid price rule by December 17, 2025.
• Continue efforts to develop ibrexafungerp and SCY-247 and potentially other product candidates.
• Seek additional capital through various financing mechanisms to fund future operations.
• Vigorously defend against ongoing securities class action and shareholder derivative complaints.

Key Dates

Recommendation

The significant reduction in net loss is primarily due to a non-cash warrant adjustment, masking underlying operational challenges. The ongoing, material dispute with GSK over the MARIO study and $30.0 million in milestones introduces substantial uncertainty regarding future revenue and development. Furthermore, the Nasdaq minimum bid price deficiency poses a near-term delisting risk. While progress on SCY-247 and the lifting of the MARIO clinical hold are positive, these are overshadowed by the financial and operational risks. The company's cash position has declined, and it anticipates needing additional capital. Given the high uncertainty and significant risks, a 'hold' recommendation is appropriate, advising investors to monitor the resolution of the GSK dispute, Nasdaq compliance, and the progress of SCY-247 before making further investment decisions.

Keywords

SCYNEXIS, SCYX, 10-Q, Biotechnology, Antifungal, Ibrexafungerp, BREXAFEMME, MARIO study, Invasive Candidiasis, SCY-247, Clinical Trials, FDA, GSK, Nasdaq Delisting, Financial Results, Drug Development, Vulvovaginal Candidiasis, Recurrent Vulvovaginal Candidiasis